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Abstract:  Introduction: Intra-arterial chemotherapy (chemosurgery) for the treatment of retinoblastoma has been 
performed more than 1600 times (more than 1400 times in Japan and 200 times in New York) over the past 20 years. 
Despite this treatment’s success some eyes cannot be saved and require enucleation. Here we report the histopathologic 
findings of the remaining intraocular tumor of eyes that were enucleated following treatment that included chemosurgery 
in New York City. 
Materials and Methodology: Independent histopathologic review of the enucleated eyes was correlated with the clinical 
findings that prompted enucleation. 
Results: Between May 1, 2006 and April 30, 2009, 56 eyes received chemosurgery at our institution, and 10 of these were 
enucleated subsequently. All were Reese Ellsworth Group 5 at enucleation. Of the 21 eyes that were treated with 
chemosurgery as the primary treatment, 1 (5%) was enucleated subsequently; its histopathology revealed residual non-
necrotic, non-calcified tumor. Of the 34 eyes treated with chemosurgery after other treatments, 9 (24%) were enucleated, 
and 5 of these eyes contained non-calcified, non-necrotic tumor. None was enucleated for complications of chemosurgery. 
All patients were alive and free of metastatic disease as of September 2009. 
Conclusions: A significant number of eyes with advanced intraocular retinoblastoma avoided enucleation as a result of 
chemosurgery. The rate of eyes that were enucleated was higher when chemosurgery was the secondary rather than the 
primary treatment. Of the eight eyes enucleated for progressive disease six had non-necrotic, non-calcified tumor cells. 
Keywords: Retinoblastoma, histopathology, chemosurgery. 
INTRODUCTION 
  Retinoblastoma may be treated successfully by 
combinations of enucleation, external beam radiation (EBR), 
systemic chemotherapy, periocular chemotherapy, and local 
treatments such as laser, cryotherapy, and brachytherapy.   
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Due to the success of these methods, treatment 
improvements have focused on maintaining the eye, 
reducing toxicities of treatments, and maximizing visual 
outcomes. Although the concept of infusing chemotherapy 
into the arterial blood supply of the eye via the carotid artery 
is not new [1, 2], improvements in interventional radiology 
techniques now permit the administration of high 
concentrations of chemotherapeutic drugs directly to the eye 
via the ophthalmic artery [3], thereby limiting the systemic 
and intracranial toxicity and increasing drug delivery to the 2    The Open Ophthalmology Journal, 2011, Volume 5  Graeber et al. 
target end organ. Japanese investigators have performed and 
described their experiences with more than 1400 infusions of 
selective intra-carotid arterial chemotherapy [3-6]. 
Previously, we described a technique for super-selective 
drug delivery, further improving the specificity of this 
technique by using a microcatheter to infuse chemotherapy 
into the ophthalmic artery (chemosurgery) [7]; we have since 
treated more than 70 eyes with more than 200 infusions. 
  There is a paucity of literature published about the 
enucleated eyes that have been treated by chemosurgery 
because relatively few eyes treated with this protocol are 
enucleated. Only one case report has been published 
describing an eye that was enucleated after extensive treat-
ment, including conventional chemotherapy, intraophthalmic 
artery and intravitreous injection of melphalan, focal laser, 
and vitrectomy with additional periorbital melphalan [8]. 
The report, however, did not comment on the histopathologic 
findings of the remaining tumor in the enucleated eye. We 
therefore now report the histopathologic findings of the 10 
eyes that were treated in New York and subsequently 
enucleated through the end of April 2009. 
MATERIALS AND METHODOLOGY 
  Institutional review board approval was obtained for the 
retrospective review of 10 charts of patients with retino-
blastoma whose tumors were treated with chemosurgery at 
this institution and who required enucleation after their 
treatment. The clinical courses of these patients, including 
their treatment regimens prior to referral and the reasons for 
referral and enucleation were reviewed. Pathologic findings 
were reviewed by a pathologist (RF) who was masked to 
clinical information. Any retinoblastoma tissue identified 
histologically was classified as necrotic, calcified, or non-
necrotic and non-calcified. The histopathologic findings 
were then compared with the clinical findings that prompted 
enucleation as documented in the written chart and by 
fundus photography. Fisher’s exact test was used to compare 
the number of enucleations in the eyes treated with primary 
chemosurgery versus those treated previously with other 
treatment modalities. 
RESULTS 
  As of April 30, 2009, 56 eyes had received chemosurgery 
at our institution, of which 10 had been enucleated (see 
Table 1 for a case summary and Fig. (1) for examples of the 
fundus photographs prior to enucleation). Of those 10 eyes, 6 
were Reese Ellsworth Group 5B, 2 were Group 5A, and 2 
were 3A at initial presentation. 9 were Reese Ellsworth 
Group 5B and 1 was Group 5A at the time of enucleation. 
Four of the patients were female, and 8 had a history of 
bilateral disease. 
  Of the 22 eyes that were treated with chemosurgery as 
the primary treatment, only 1 was enucleated for tumor 
progression and histopathologic review revealed residual 
non-necrotic, non-calcified cells. Of the 34 eyes treated with 
chemosurgery after other treatments, 9 were enucleated—5 
for tumor progression, 2 for insufficient regression, 1 for 
persistent retinal detachment, and 1 for secondary glaucoma  
from rubeosis iridis with a painful eye. Seven of these 9 
patients had been recommended for enucleation and received 
chemosurgery as salvage therapy--5 received EBR after 
systemic chemoreduction therapy failed to eradicate the 
tumor burden, 1 received EBR as primary treatment, and 1 
failed systemic chemoreduction and periocular carboplatin. 
The contralateral eye of three of these patients had been 
enucleated due to retinoblastoma at presentation to this 
institution. 
  The mean time that the eye was maintained after initial 
treatment with chemosurgery for eyes receiving 
chemosurgery as salvage treatment was 143 days (range 26 
to 343 days). For all eyes, the mean time to enucleation after 
initial treatment with chemosurgery was 187 days (range 26 
days to 484 days). The mean time from diagnosis to 
enucleation for all patients was 675 days (range 200 to 1548 
days). More eyes were enucleated from the group that 
received chemosurgery as secondary treatment than were 
enucleated from the group that had received chemosurgery 
as primary treatment (P =.036). 
  On masked histopathologic review, 6 of the 10 
enucleated eyes contained persistent, non-necrotic, non-
calcified tumor, 2 with residual tumor that was either 
calcified or necrotic, and 1 with no evidence of tumor (Table 
1,  Fig.  2). Slides from one patient were not available for 
histopathologic review. Eight of the 10 eyes had no evidence 
of invasive disease. Invasion into the choroid, superficial 
invasion of the sclera, and invasion of the optic nerve past 
the lamina cribrosa (but not to the resection margin) was 
identified in only one eye. There was no evidence of retinal 
arterial occlusion in any of the enucleated specimens. 
DISCUSSION 
  This report is the first to detail the histopathologic 
findings of the remaining tumor found in eyes enucleated 
after treatment with chemosurgery. Of these 9 eyes that were 
histopathologically reviewed, one had no residual tumor, two 
had evidence of calcified or necrotic cells, and six had 
evidence of non-necrotic, non-calcified tumor. Several 
previous studies have commented on the viability of tumor 
in histopathologic specimens. From histopathological 
findings alone, it is not possible to identify which tumor cells 
might be viable. One could not say with certainty if tumor 
cells that are neither necrotic nor calcified are viable, but 
calficified and necrotic cells are not considered to be capable 
of contributing to tumor growth, invasion, or metastasis. We, 
therefore, avoided defining viable versus non-viable tumor 
and commented only on the presence or absence of necrotic 
or calcified cells. 
  Of the 6 eyes that were enucleated for progression of 
disease, 2 of them had either complete tumor regression or 
calcified tumor on histopathologic review (Fig. 1a and Fig. 
1b, respectively). This disconnect between the clinical 
findings that prompted enucleation and the histopathologic 
findings raises the question of whether the clinical regression 
patterns in eyes treated with chemosurgery are different from 
eyes treated by other treatment modalities. With more 
experience and with definition of the regression pattern in 
these patients, it may be possible in the future to monitor 
these eyes safely without resorting to enucleation. 
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  It is not the purpose of this study to specifically identify 
any intraocular toxicity from chemosurgery nor is that 
possible. Nine of these eyes had received extensive, 
multimodal treatments to the eye before chemosurgery was 
attempted as salvage. These nine eyes had different 
combinations of prior multiagent systemic chemotherapy, 
EBR, brachytherapy, cryotherapy and laser so it would have 
been impossible to specifically identify toxicity of the 
chemosurgery itself. The one eye that was primarily treated 
with chemosurgery and then enucleated did not show any 
toxicity in the optic nerve or other ophthalmic structures. In 
addition, no eye showed evidence of retinal arterial 
occlusion. None of the eyes in this series was enucleated 
because of toxicity related to chemosurgery. One eye 
presented to this institution with a complication of prior 
treatment—secondary glaucoma from rubeosis iridis. This 
complication has been associated with EBR [9] and was the 
primary reason for enucleation. 
  Chemosurgery was a salvage treatment for 7 of the 9 
eyes that were previously treated with other modalities. In 
two eyes, we detected histopathologic features associated 
with risk for local and systemic relapse [10-16]. In one of 
these eyes (Case 8) we detected tumor in the ciliary body 
with seeding of the anterior chamber (Fig. 2c), and in the 
other eye (Case 10) we detected choroidal invasion, 
superficial scleral invasion, and invasion of the optic nerve 
beyond the lamina cribrosa. 
Table 1.   
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1  bilateral OS 5A 5A no  --  yes  --  no  progression  yes no  3  M
7  3 C
8  3 progression 
Complete 
tumor 
regression 
2 bilateral  OS  5B 5B  yes 2 yes -- no  recurrence  yes no  1 M
7 1  N/A  -- secondary 
glaucoma 
calcified 
cells 
3 bilateral  OS 5B 5B  yes -- yes -- yes  recurrence  yes no  3  M
7 3 T
9  2 progression  calcified 
cells 
4 bilateral  OD  5B 5B  yes  15 yes P yes  persistent  
tumor 
yes yes  5  M
7 5 T
9 2  insufficient 
regression 
N/A 
5 bilateral  OD  5B  5B  yes 5 yes P yes  persistent  
 tumor  yes yes  4  M
7 4 T
9 4 RD/VH 
non- 
necrotic/ 
non- 
calcified 
6 unilateral  OD 3A 5B yes  4  no  --  yes 
inability to  
tolerate  
systemic  
chemo 
no no  3 M
7 3 T
9 1  progression 
non- 
necrotic/ 
non- 
calcified 
7 bilateral  OS  3A  5B no -- no B yes  recurrence  no no  6 M
7 6 T
9 3  insufficient 
regression 
non- 
necrotic/ 
non- 
calcified 
8  unilateral  OD  5B  5B  no -- no B yes primary  
treatment  no no  3 M
7 3  N/A  --  progression 
non- 
necrotic/ 
non- 
calcified 
9  bilateral OS 5A 5B yes  5  No  P  yes  recurrence  yes no  3  M
7 3  N/A  --  progression 
non- 
necrotic/ 
non- 
calcified 
10 bilateral  OD 5B 5B yes  8  yes  --  yes  recurrence  yes yes  6  M
7 6 T
9 1  progression 
non- 
necrotic/ 
non- 
calcified 
1 EE= eye enucleated 
2 RE = Reese Ellsworth group 
3EBR=External beam radiation 
4B/P = Brachytherapy/periocular chemotherapy 
5FT = focal therapy, including laser and 
cryotherapy 
 6CS = chemosurgery 
7M = melphalan, 
8C = carboplatin, 
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(a) 
 
(b) 
 
(c) 
 
Fig. (1).  a) Fundus photograph prior to enucleation of eye with 
complete tumor regression on histopathologic review (Case 1). (b) 
Fundus photograph prior to enucleation of eye with necrotic and 
calcified cells on histopathologic review (Case 3). (c) Fundus 
photograph prior to enucleation of an eye with non-necrotic, non-
calcified cells on histopathologic review (Case 7). 
(a) 
 
(b) 
 
(c) 
 
Fig. (2). Hematoxylin and eosin stain of histopathology. (a) 
Histopathology of patient with calcified cells (Case 2). (b) 
Histopathology of non-necrotic, non-calcified tumor, low power 
(Case 8). (c) High power view of boxed area in Figure 2b. Arrows 
indentify large areas of non-necrotic, non-calcified cells (Case 8). 
CONCLUSION 
  Overall, chemosurgery has been successful in treating 
eyes with retinoblastoma and preventing enucleation. Of the 
22 patients who had chemosurgery as their primary Histopathology After Treatment with Chemosurgery  The Open Ophthalmology Journal, 2011, Volume 5    5 
treatment, fewer than 5% of the eyes were enucleated 
subsequently. Of the 34 eyes that had failed other treatments, 
26% were enucleated, almost all of which received 
chemosurgery as salvage treatment. On average, the patients 
were able to retain the treated eye for over 5.5 additional 
months. Further investigation is needed to identify histologic 
evidence of treatment toxicity and to correlate clinical 
features with histopathological results.  
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